Demographic and clinical profile of patients suffering prolonged severe hypoxia in COVID-19.
Expert Rev Respir Med
; 16(9): 1017-1021, 2022 09.
Article
in English
| MEDLINE | ID: covidwho-2037276
ABSTRACT
BACKGROUND:
Coronavirus disease 2019 (COVID-19) may result in rapid onset of hypoxemic respiratory failure. This study aimed to characterize the factors and outcomes associated with prolonged hypoxia in patients with COVID-19. Prolonged severe hypoxia (PSH) was defined as hypoxia requiring ≥6 L/min of oxygen by nasal cannula or equivalent for more than 10 days. RESEARCH DESIGN ANDMETHODS:
This study was designed as a single-center retrospective analysis. Multivariable logistic regression was utilized to assess factors associated with PSH.RESULTS:
The sample included 554 patients with 117 (21%) having PSH. Median length of stay of patients with PSH was significantly longer (median IQR 18 days vs 6 days, p < 0.0001). Patients with PSH had significantly higher rates of venous thromboembolism (p < 0.0001) and major bleeding (p < 0.004). The presence of cirrhosis (OR 3.32, 95% CI [1.02 to 10.83]) and hypertension (OR 1.99, 95% CI [1.12 to 3.53]) were independently associated with PSH, while outpatient use of anti-platelet agents had an inverse association (OR 0.57, 95% CI [0.36 to 0.91]).CONCLUSION:
PSH is associated with increased length of stay, morbidity, and mortality. Hypertension and liver cirrhosis were significantly associated with higher odds of PSH, while use of anti-platelet therapy had a protective effect.Keywords
Full text:
Available
Collection:
International databases
Database:
MEDLINE
Main subject:
COVID-19
/
Hypoxia
Type of study:
Observational study
/
Prognostic study
Topics:
Long Covid
Limits:
Humans
Language:
English
Journal:
Expert Rev Respir Med
Year:
2022
Document Type:
Article
Affiliation country:
17476348.2022.2126354
Similar
MEDLINE
...
LILACS
LIS